01 / STACK OVERVIEW

What Is The Wolverine Stack?

      The Wolverine Stack is the most powerful peptide combination for accelerated healing and tissue regeneration. Named for its near-superhuman recovery profile — BPC-157 and TB-500 attack tissue repair from two completely different mechanisms, creating a synergistic effect that neither compound achieves alone. Used by elite athletes, post-surgical patients, and anyone with chronic injuries that conventional medicine can't resolve.
    

BPC-157

10mg vial · 33.3 mcg/unit

LOCAL REPAIR AGENT

Body Protection Compound — 15 amino acid peptide isolated from gastric juice. Activates growth factor receptors (VEGFR2, FGFR) at injury sites. Accelerates angiogenesis (new blood vessel formation), tendon-to-bone attachment, ligament healing, and gut repair. Works locally at the injury site — inject near damaged tissue for maximum effect.

TB-500

10mg vial · 33.3 mcg/unit

SYSTEMIC REPAIR AGENT

Synthetic fragment of Thymosin Beta-4. Binds actin — the protein in all cells that drives cellular motility and structural repair. Reduces systemic inflammation via NF-κB pathway inhibition. Promotes stem cell migration to injury sites throughout the entire body. Works systemically — one injection repairs everywhere.

20mg

TOTAL STACK

2

VIALS

Dual

MECHANISM

8–12w

CYCLE LENGTH

02 / SYNERGY MECHANISM

Why These Two Together

L

BPC-157 — LOCAL PRECISION

Concentrates repair signals at the specific injury site. Accelerates local angiogenesis (blood flow to damaged tissue), stimulates local growth factor cascades, and drives tendon/ligament fibroblast proliferation. Think of it as calling the repair crew directly to the worksite.

S

TB-500 — SYSTEMIC AMPLIFICATION

Floods the body with stem cells, reduces systemic inflammation, and upregulates actin availability in every cell. Creates the optimal systemic environment for the local BPC-157 repair process to work. Think of it as clearing traffic, reducing friction, and bringing reinforcements everywhere.

2×

COMBINED EFFECT

Animal studies show the combination heals tendon injuries significantly faster than either peptide alone. BPC-157 drives local tissue architecture reconstruction while TB-500 provides the cellular building blocks and removes inflammatory barriers. The result: the fastest non-surgical tissue repair protocol in peptide research.

Injury Protocol: For acute injuries — BPC-157 injected subcutaneously as close to the injury site as possible. TB-500 injected into any SC site (systemic distribution). Run both simultaneously for maximum effect.

03 / RECONSTITUTION

Vial Preparation — Two Formats

⭐ WOLVERINE PRE-BLEND — 20mg VIAL

10mg BPC-157 + 10mg TB-500 · pre-mixed in one vial

20mg total + 3.0 mL BAC water = 66.7 mcg of EACH per unit

Standard dose (500mcg each): 7.5 units / 0.075 mL

Loading dose (750mcg each): 11.3 units / 0.113 mL

Aggressive (1mg each): 15 units / 0.15 mL

Best option for most users. One injection delivers both peptides at the same 1:1 ratio. Simpler, cheaper than buying separate vials, and BPC-157 + TB-500 are pharmacologically compatible (no methionine oxidation, no copper — they share the same BAC water buffer cleanly). Compounding pharmacies ship this as "Wolverine Blend" or "BPC+TB 20mg".

— OR buy them separately —

BPC-157 — 10mg VIAL (standalone)

10mg + 3.0 mL BAC water

33.3 mcg per unit

250mcg: 7.5 units / 0.075 mL

500mcg: 15 units / 0.15 mL

750mcg: 22.5 units / 0.225 mL

TB-500 — 10mg VIAL (standalone)

10mg + 3.0 mL BAC water

33.3 mcg per unit

500mcg: 15 units / 0.15 mL

1mg: 30 units / 0.30 mL

2mg: 60 units / 0.60 mL

If you have separate vials, you can still co-inject them in one syringe. BPC-157 and TB-500 are compatible — draw each one into the same insulin syringe, inject together SubQ. No degradation risk since neither contains copper or reactive metals.

🧊

RECONSTITUTED SHELF LIFE

30 days after mixing

BPC-157 + TB-500 blend. 30-day window.

            Storage: 2–8°C (fridge) · Protected from light · Do NOT freeze

            Preload syringes/cartridges to minimize vial disturbance

Storage: Both vials: lyophilized powder stable at room temp 6 months. After reconstitution: refrigerate (36–46°F / 2–8°C), use within 28–30 days. Protect from light. Do NOT freeze reconstituted vials.

04 / DOSING PROTOCOL

Stack Dose Ranges

BPC-157

LEVEL	DOSE	FREQUENCY	INJECTION SITE
LOW	250mcg / day	Daily	SC near injury site or abdominal fat pad
STANDARD	500mcg / day	Daily	SC near injury (preferred) or any SC site
HIGH	750mcg / day	Daily	Can split AM/PM — 375mcg × 2

TB-500

LEVEL	DOSE	FREQUENCY	NOTES
LOADING	2–4mg / week	2× weekly (Weeks 1–4)	Front-load for acute injury or first cycle
MAINTENANCE	2mg / week	1–2× weekly (Weeks 5+)	Standard maintenance. Split 1mg × 2 injections.
HIGH	4mg / week	2× weekly	Severe injury or rapid recovery protocol

05 / INJECTION SCHEDULE

Weekly Protocol

PEPTIDE

MON / THU

DAILY (TUE–SUN)

SITE

BPC-157

✓ 500mcg

✓ 500mcg daily

Near injury / abdomen

TB-500

✓ 1–2mg each

— rest days

Any SC site, rotate

Timing: BPC-157 — no fasting required. Can inject any time. Best results when injected as close to the injury site as possible. TB-500 — no fasting required. Injected 2× weekly regardless of BPC-157 timing.

Acute Injury Protocol (Weeks 1–2): TB-500 loading dose 2mg every 3–4 days + BPC-157 750mcg daily split AM/PM. Front-loading accelerates the inflammatory-to-regenerative phase transition.

06 / BIOMARKER MONITORING

Recommended Lab Panel

INFLAMMATION — PRIMARY RECOVERY MARKERS

MARKER	CLINICAL RANGE	OPTIMAL TARGET	NOTES
hs-CRPhigh-sensitivity C-reactive protein	CLINICAL<3.0 mg/L	OPTIMAL<0.5 mg/L	Primary inflammation marker — should drop significantly within 4–6 weeks of stack use
IL-6interleukin-6	CLINICAL<7 pg/mL	OPTIMAL<2 pg/mL	Pro-inflammatory cytokine — TB-500 NF-κB inhibition drives this down
ESRerythrocyte sedimentation rate	CLINICAL0–20 mm/hr	OPTIMAL<10 mm/hr	Secondary inflammation marker — tracks alongside CRP for recovery trajectory

TISSUE REPAIR MARKERS

MARKER	METHOD	NOTES
Ultrasound / MRIradiographic assessment	Pre/post cycle imaging	Tendon, ligament, muscle imaging — before and after 8–12 week cycle. Objective tissue healing confirmation.
VEGFvascular endothelial growth factor	Serum — optional	BPC-157 drives VEGF upregulation (angiogenesis). Elevated VEGF confirms mechanism is active.
Collagen Cross-linksCTX / P1NP	Serum — optional	P1NP indicates new collagen synthesis (repair). CTX indicates breakdown. Improving P1NP:CTX ratio = net tissue building.

SAFETY PANEL

MARKER	CLINICAL RANGE	NOTES
CBCcomplete blood count	CLINICALStandard	Baseline and at 8 weeks. Both peptides have excellent safety profile — monitoring confirms tolerability.
CMPcomprehensive metabolic panel	CLINICALStandard	Liver and kidney function. BPC-157 has hepatoprotective properties — expect normal or improved values.

07 / CYCLE PROTOCOL

Administration Schedule

CYCLE LENGTH

8–12 Weeks

ACUTE INJURY PHASE (Wks 1–4)

TB-500: 2–4mg loading 2×/week. BPC-157: 500–750mcg daily. Aggressive front-load to drive rapid phase transition from inflammation to repair.

MAINTENANCE PHASE (Wks 5–12)

TB-500: 2mg 1–2×/week. BPC-157: 250–500mcg daily. Sustain repair environment while tissue remodeling completes.

OFF PERIOD

4–8 weeks between cycles for healthy individuals. For ongoing injury management, some practitioners run BPC-157 indefinitely at low maintenance dose (250mcg/day).

UPGRADE: KLOW STACK

Add KPV 10mg + GHK-Cu 50mg to this stack → full KLOW protocol. Adds gut/mucosal repair (KPV), skin/collagen matrix (GHK-Cu), and deeper anti-inflammatory coverage.

REQUIRES

2 vials (BPC-157 + TB-500) · BAC water · Apex V3 Pen · Refrigeration post-reconstitution

⚠ Research reference only. BPC-157 and TB-500 are not FDA-approved for human therapeutic use. Information sourced from published clinical and preclinical literature. Consult a qualified medical provider before use.